On May 19th, during the congress of EuroPCR held in Paris, France, the original integrated cardiovascular precision assessment technology (μQFR + AMR + RWS) led by Prof. Shengxian Tu and Prof. Yazhu Chen, won the global Cardiovascular Instrument Innovation Competition. It is the first time that researcher from Asia-pacific region has won the award. Prof. William Wijns, President of EuroPCR, Prof. Jean Fajadet, Vice President of EuroPCR, Dr. Jonathan Schwartz, medical director of The Charlotte Sanger Heart and Vascular Center, USA, presented the winning team (Dr. Jiayue Huang accepted the award on behalf of Prof. Shengxian Tu) with the trophy and the Jon DeHaan Foundation award of us $200,000 for advancing the clinical transformation of the winning technology.

Shengxian Tu 's team won the Wold Cardiovascular Device Innovation Award 

Dr. Jiayue Huang accepted the award on behalf of Prof. Shengxian Tu

Between Dec 25, 2018, and Jan 19, 2020, 3847 patients were enrolled. After exclusion of 22 patients who elected not to undergo PCI or who were withdrawn by their physicians, 3825 participants were included in the intention-to-treat population (1913 in the QFR-guided group and 1912 in the angiography-guided group). The mean age was 62·7 years (SD 10·1), 2699 (70·6%) were men and 1126 (29·4%) were women, 1295 (33·9%) had diabetes, and 2428 (63·5%) presented with an acute coronary syndrome. The 1-year primary endpoint occurred in 110 (Kaplan-Meier estimated rate 5·8%) participants in the QFR-guided group and in 167 (8·8%) participants in the angiography-guided group (difference, –3·0% [95% CI –4·7 to –1·4]; hazard ratio 0·65 [95% CI 0·51 to 0·83]; p=0·0004), driven by fewer myocardial infarctions and ischaemia-driven revascularisations in the QFR-guided group than in the angiography-guided group.

Prof. Shengxian Tu first published the clinical validation results of the radial wall strain (RWS) technique and FAVOR III China RWS substudy online

Major findings of FAVOR III China RWS substudy

As the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), EuroPCR is a patient-oriented Course built by and for the community covering the latest innovations and advances in cardiovascular interventions. ​